Today’s Shorts Alert: What Will Happen to CELLCEUTIX CORPORATION (OTCMKTS:CTIX) Next? The Stock Has Increase in Shorts

November 30, 2016 - By kentuckypostne   ·   0 Comments

Today's Shorts Alert: What Will Happen to CELLCEUTIX CORPORATION (OTCMKTS:CTIX) Next? The Stock Has Increase in Shorts

The stock of CELLCEUTIX CORPORATION (OTCMKTS:CTIX) registered an increase of 3.92% in short interest. CTIX’s total short interest was 747,700 shares in November as published by FINRA. Its up 3.92% from 719,500 shares, reported previously. With 347,000 shares average volume, it will take short sellers 2 days to cover their CTIX’s short positions. About 104,813 shares traded hands. Cellceutix Corp (OTCMKTS:CTIX) has declined 27.78% since April 27, 2016 and is downtrending. It has underperformed by 33.00% the S&P500.

Cellceutix Corporation is a clinical-stage biopharmaceutical company. The company has a market cap of $152.80 million. The Firm is engaged in developing therapies with oncology, dermatology and antimicrobial applications. It currently has negative earnings. Cellceutix owns the rights to various drug compounds, including Kevetrin (thioureidobutyronitrile), which is its anti-cancer compound; Prurisol (KM-133), which is in development for psoriasis, and Brilacidin, which is its drug in a class of compounds known as defensin-mimetics.

CTIX Company Profile

Cellceutix Corporation (Cellceutix), incorporated on August 1, 2005, is a clinical-stage biopharmaceutical company. The Firm is engaged in developing therapies with oncology, dermatology and antimicrobial applications. Cellceutix owns the rights to various drug compounds, including Kevetrin (thioureidobutyronitrile), which is its anti-cancer compound; Prurisol (KM-133), which is in development for psoriasis, and Brilacidin, which is its drug in a class of compounds known as defensin-mimetics. The Company’s clinical trials focus on evaluating its drug candidates, including Kevetrin for the treatment of cancers; Prurisol for the treatment of psoriasis, and Brilacidin for treatments of skin infections, prevention of oral mucositis complicating chemoradiation treatment for cancer, and ulcerative proctitis. The Firm focuses on developing small molecule therapies to treat diseases in the areas of cancer, antibiotics and inflammatory disease.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By kentuckypostne


Readers Comments (0)





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>